During influenza pandemics, secondary pneumococcal infections cause excessive mortality. However, the current 13-valent pneumococcal conjugate vaccine, PCV13, provides only limited protection against secondary infection. Therefore, a more effective pneumococcal vaccine is required to protect against secondary pneumococcal infections. Here, intranasal immunization with an attenuated pneumococcal pep27 mutant provides protection from influenza virus infection, and also from secondary pneumococcal challenge. These results indicate that mucosal immunity might be an effective way to reduce the morbidity and mortality due to secondary pneumococcal infections during influenza pandemics.
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Streptococcus pneumoniae (pneumococcus) and influenza A virus (IAV) are major causative agents for respiratory infections [1, 2] . Although IAV alone can cause respiratory disease, secondary infection with pneumococcus following IAV infection increases mortality [3] . It has been reported that pneumococcus is responsible for much of the mortality in both the 1918 Spanish influenza pandemic [4] and the 2009 H1N1 pandemic [5] . However, the currently available 13-valent pneumococcal conjugate vaccine (PCV13), which includes serotype 3 polysaccharide, failed to protect against secondary serotype 3 pneumococcal infection following influenza infection, indicating limited efficacy of the PCV13 [6] .
Previously, we demonstrated that intranasal immunization with an attenuated pneumococcus pep27 mutant (Δpep27, without adjuvant) could protect a host from lethal pneumococcal challenge serotype independently; it also lowered bacterial colonization in the nasopharynx. Furthermore, we reported that Δpep27 immunization provided long-term protection by inducing the secretion of various cytokines [7] . However, whether Δpep27 immunization provides effective protection against secondary pneumococcal challenge following influenza infection remains unclear. In this study, we demonstrated that Δpep27 immunization effectively protects against secondary pneumococcal challenge after influenza virus infection by lessening both the viral and the bacterial burden in the lung.
METHODS

Infectious Agents
Streptococcus pneumoniae serotype 2 (D39) wild-type, serotype 3 (A66.1), serotype 6A (BG7322), and the THpep27 mutant (D39 Δpep27) were cultured and used as previously described [7] .
Influenza virus strain A/California/04/2009 (H1N1) was propagated in embryonated eggs as previously described [8] . In brief, the virus was cultured in the allantoic cavity of 10-dayold embryonated hen eggs for 72 hours. The allantoic fluid was harvested by centrifugation, then aliquoted and stored at -80°C.
Mice, Immunization, Infection, and Challenge
All experiments were performed on 6-to 8-week-old female BALB/cAnHsd mice (Koatech, Korea), and all procedures were approved by the Institutional Animal Care and Use Committee at the International Vaccine Institute. Mice were immunized with approximately 1 × 10 8 colony-forming units (CFU) of Δpep27 in 50 μL of phosphate-buffered saline (PBS) via the intranasal route 3 times at 1-week intervals. Ten to 12 days (short-term) or 30 days (long-term) after the last immunization, 0.02 LD 50 (50% lethal dose) of H1N1 influenza virus in 50 μL PBS was administered by the intranasal route. Body weight was then monitored every day. Mice were challenged with 1 × 10 8 CFU of D39 in 50 μL PBS via the intranasal route 10-12 days after influenza infection, and the survival rate was determined.
Serum Immunoglobulin G Titer Determination
One week after the last immunization, blood was collected from the retro-orbital plexus, and serum was obtained by centrifugation. The samples were stored at -80°C until further analysis. Serum antibody titers against pneumococcal antigens were measured by enzyme-linked immunosorbent assay as previously described [9, 10] .
Viral and Bacterial Titration in the Lung
To determine virus titers, groups of 4 BALB/c mice were immunized with the Δpep27 mutant and infected with the H1N1 influenza virus, as described above. Virus titers were determined by endpoint dilution in Madin-Darby canine kidney (MDCK) cells, then expressed as 50% tissue culture infectious dose (TCID 50 ) [8] .
Bacterial load was analyzed as previously described [10] . In brief, lungs were removed from each mouse 24 hours after D39 challenge, homogenized, and serially diluted on blood agar plates containing 5 μg/mL of gentamicin.
RESULTS
Δpep27 Immunization Protects Mice From Secondary Pneumococcal Challenge
To investigate the protective effect of Δpep27 immunization on secondary pneumococcal infection, mice were infected with 0.02 LD 50 of H1N1 influenza virus. Ten days post-influenza virus infection, mice were challenged with the virulent pneumococcal strain D39, and the survival rate was monitored. While nonimmunized mice (PBS/H1N1) succumbed to pneumonia after D39 challenge, most immunized mice (THpep27/ H1N1) successfully survived after D39 challenge ( Figure 1A) . One month postimmunization, immunized mice (THpep27/ H1N1) still successfully survived, whereas nonimmunized mice (PBS/H1N1) succumbed to secondary pneumococcal infection ( Figure 1B ). This suggests that Δpep27 immunization protected mice from secondary pneumococcal infection after both shortterm and long-term periods of time. Previously, it was shown that Δpep27 immunization could induce immunoglobulin G (IgG) and protect mice from heterologous pneumococcal challenge [7] . Here, we analyzed whether Δpep27 immunization could raise antibody titers against whole bacterial cells as well as specific antigens. Our results showed that Δpep27 immunization increased IgG titers against strains of capsular serotypes 3, 6A, and type 2 (D39) whole cells. This increase was significantly higher than in the nonimmunized controls ( Figure 1C Ten days (A and C) or 30 days (B) postimmunization, influenza followed by Streptococcus pneumoniae D39 was used for challenge via the intranasal route, and survival was monitored for 10 days. Significant differences were determined with the Mantel-Cox test (**P < .01, ***P < .001). One week after the final immunization, sera were harvested from mice, and immunoglobulin G (IgG) levels against 3 capsular types (2, 3, and 6A) of pneumococcal whole cells or specific antigens (C) were determined by enzyme-linked immunosorbent assay. The data was represented as mean ± standard error of the mean. Significant differences between the 2 groups were determined by unpaired t test (***P < .001). Lung homogenates were plated on agar 24 hours after S. pneumoniae D39 challenge to quantify the bacterial burden as log 10 colony-forming units (CFU)/mL (D). Horizontal lines represent geometric mean log 10 CFU/mL. Significant differences were determined by 1-way analysis of variance.
against both homologous and heterologous pneumococcal strains. When IgG titers against specific antigens (PspA protein and type 2 capsular polysaccharide [CPS]) were determined, immunization with Δpep27 increased antibody titers against PspA protein but not type 2 CPS ( Figure 1C) . Moreover, when the bacterial burden after pneumococcal challenge was analyzed, all immunized mice showed a much lower bacterial burden in the lung ( Figure 1D ). This indicated that Δpep27 immunization successfully protected the mice from secondary pneumococcal challenge after influenza infection.
Δpep27 Immunization Decreased Viral and Bacterial Burden in the Lung
To investigate whether Δpep27 immunization also attenuated the influenza virus load, we monitored body weight loss after influenza virus infection. Interestingly, no Δpep27-immunized mice showed weight loss after influenza infection, whereas the nonimmunized mice showed drastic weight loss (Figure 2A) . Because Δpep27 immunization protected against weight loss from influenza virus infection, we further determined whether Δpep27 immunization affected the influenza virus burden in the lung by determining the TCID 50 of lungs from influenza-infected mice. Surprisingly, immunized mice showed significantly lower virus titers in the lung than nonimmunized mice ( Figure 2B ). However, this difference seemed to be <10-fold. These results indicated that Δpep27 immunization not only protected against pneumococcal infection, but also ameliorated influenza virus infection.
DISCUSSION
To prevent pneumococcal diseases, a pneumococcal polysaccharide conjugate vaccine has been introduced. However, this vaccine has limited efficacy, especially against secondary pneumococcal infections following influenza virus infection [6] . Thus, a new type of pneumococcal vaccine with substantially better protection is needed.
In this study, we determined that Δpep27 could protect mice from secondary pneumococcal challenge after influenza virus infection by lowering the bacterial burden in the lung. In contrast, a nonimmunized group of mice showed almost 60% greater mortality with a high bacterial load after pneumococcal challenge. It is thought that Δpep27 immunization induces secretory immunoglobulin A production and provides serotype-independent protection [7] . Unexpectedly, Δpep27 elicited antibodies against PspA but not against CPSs. The latter are major pneumococcal virulence factors, suggesting an intricate differential antibody response underlying the enhanced host protection.
Surprisingly, Δpep27 immunization alone protected against influenza infection and against pneumococcal challenge by reducing viral titers in the lung after infection. This protection against influenza virus infection may be due to an upregulation of interferon (IFN) and interleukin 17A (IL-17A) by innate immune cells such as macrophages, natural killer cells, and granulocytes (as these cells are reported to play a role in protecting against respiratory infection) [11] [12] [13] . It has also been reported that Δpep27 immunization induced IFN-γ and IL-17A production [7] . Therefore, the question of whether IFN-γ and IL-17A (specifically induced by Δpep27) enhance protection against influenza virus infection needs further verification.
Recently, the anti-inflammatory cytokine transforming growth factor beta (TGF-β) was shown to be responsible for protection against influenza virus in ovalbumin-induced asthmatic mice [14] . Asthmatic mice were resistant to influenza virus infection. This resistance was not attributed to enhanced Protective effect of THpep27 immunization via inhibition of influenza virus replication. Groups of 10 mice were infected with influenza virus via the intranasal route, and body weights of the mice were monitored for 11 days (A). Significant differences were determined by 1-way analysis of variance (***P < .001), and statistical difference represented on the figure indicates the difference between phosphate-buffered saline (PBS)/H1N1 and THpep27/H1N1 as a representative difference. Five days after influenza infection, lung homogenate supernatants were harvested, and the virus titer of each group was measured and represented as log 10 50% tissue culture infectious dose (TCID 50 )/mL (B). Horizontal lines represent geometric mean log 10 TCID 50 /mL. Significant differences were determined by unpaired t test (***P < .001).
viral clearance via upregulated immunity, but rather to attenuated tissue damage and diminished inflammation via TGF-β [14] . Whether TGF-β plays an important role in the Δpep27-mediated protection against primary or secondary pneumococcal infection warrants further study. In conclusion, Δpep27 immunization is a novel and safe way to overcome both invasive pneumococcal diseases and severe secondary infections following influenza infection during influenza pandemics.
Notes
